Gene editing

AskBio Names Mansuo Shannon Chief Scientific Officer

Retrieved on: 
Martedì, Aprile 9, 2024
Eli Lilly, Alzheimer's disease, Gene editing, Princeton University, MIT, Research, Bayer, Chugai Pharmaceutical Co., Doctor of Philosophy, Samulski, Therapy, Eli Lilly and Company, CSO, Molecular biology, Management

Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company

Key Points: 
  • Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
    Co-Founder and former Chief Scientific Officer R. Jude Samulski to remain member of AskBio Board of Directors
    Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that on April 8, 2024, Mansuo Shannon, PhD, was named the company’s next Chief Scientific Officer (CSO).
  • Shannon joins AskBio from Prevail Therapeutics, where she also served as CSO.
  • Reporting to Gustavo Pesquin, Chief Executive Officer (CEO), Shannon will be a member of AskBio’s Executive Leadership Team and head its R&D organization.
  • As part of her role as CSO at AskBio, Shannon will develop and implement the company’s future R&D strategy.

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Retrieved on: 
Lunedì, Aprile 8, 2024
Euronext Growth, Gene, DNA, HSPC, Society, Therapy, Cell, Gene editing, Vaccine

Cellectis presents the development of a novel gene editing process, leveraging the TALEN® technology and non-viral DNA template delivery, enabling highly efficient gene correction and gene insertion in hematopoietic stem and progenitor cells (HSPCs).

Key Points: 
  • Cellectis presents the development of a novel gene editing process, leveraging the TALEN® technology and non-viral DNA template delivery, enabling highly efficient gene correction and gene insertion in hematopoietic stem and progenitor cells (HSPCs).
  • Gene therapy using hematopoietic and progenitor stem cells (HSPC) has the potential to provide a lifelong supply of genetically encoded therapeutics.
  • Gene editing strategies enabling supra-endogenous expression of therapeutics often rely on constitutive promoters resulting in transgene overexpression irrespective of cellular differentiation, which could be detrimental for HSPC function.
  • Full abstracts and presentations will be available on Cellectis’ website following the event:

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Lunedì, Aprile 8, 2024
Computational biology, Malignancy, Canadian Aviation Regulations, Gene editing, Bone disease, Cell, Hook effect, CXCR4, Enfortumab vedotin, Synthetic biology, Patient, Neoplasm, Epitope, Differentiable function, Ink, PBMC, Protein engineering, HLA, Science, Cytotoxicity, AACR, Phenotype, Therapy, IPSC, Skin, Inflammation, Prognosis, Carcinogenesis, Rejection, CD22, VHH, Poster, NK, Century, Autoimmunity, Bone marrow, Engineering, CD19, Vaccine

PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.

Key Points: 
  • PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the AACR Annual Meeting 2024.
  • This novel CAR was engineered and tested in iPSC-derived gamma-delta T cells, showing in vitro tumor cell cytotoxicity.
  • These findings support the continued examination of a CD19xCD22 bispecific CAR for off-the-shelf allogeneic cell therapy to expand patient access beyond CD19 CAR-T cell therapies.
  • In these preclinical studies, Century identified novel single-domain antibodies (VHH) that bind to multiple epitopes on the NECTIN4 extracellular domain.

Verve Therapeutics Announces Updates on its PCSK9 Program

Retrieved on: 
Martedì, Aprile 2, 2024
LDLR, Cardiovascular disease, Gene editing, PCSK9, ALT, Patient, RNA, Health care, Health Canada, IND, N-Acetylgalactosamine, MHRA, Asialoglycoprotein receptor, Clinical trial, CTAS, Therapy, Bleeding, Safety, Moyamoya disease, DSMB, FDA, Liver, ASCVD, LNP, Medsafe, Hypercholesterolemia, Food, Pharmaceutical industry

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced updates from the Heart-1 Phase 1b clinical trial of VERVE-101 and clearance of its Clinical Trial Applications (CTAs) by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada for VERVE-102, with the Heart-2 Phase 1b clinical trial expected to initiate in the second quarter of this year.

Key Points: 
  • Six participants have been dosed at 0.45 mg/kg of VERVE-101, with a total of 13 participants dosed in the study.
  • Verve is conducting an investigation into the laboratory abnormalities and based on those results, expects to work with regulatory authorities to define a path forward for VERVE-101.
  • Verve is now prioritizing the development of VERVE-102 and the initiation of the Heart-2 clinical trial.
  • VERVE-102 uses the same base editor and guide RNA for PCSK9 but a different lipid nanoparticle (LNP) delivery system than VERVE-101.

Spotlighting Excellence: Keiretsu Forum Curates Premiere Investment Opportunities for the 2024 Angel Capital Association Innovation Funders Showcase

Retrieved on: 
Martedì, Aprile 2, 2024
Keiretsu Forum, Angel Capital Association, Gene editing, Philosophy, Internet of things, Patient, Kidney failure, ALM, Angel, Entrepreneurship, Software, Keiretsu, CRISPER, Engineering, Therapy, Summit, ACA, Financial services

PHILADELPHIA, April 02, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum Mid-Atlantic , South-East and Texas, leaders in angel investing, proudly announces its sponsorship of select pioneering companies at the annual Innovation Funders Spotlight during the 2024 Angel Capital Association (ACA) Summit.

Key Points: 
  • PHILADELPHIA, April 02, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum Mid-Atlantic , South-East and Texas, leaders in angel investing, proudly announces its sponsorship of select pioneering companies at the annual Innovation Funders Spotlight during the 2024 Angel Capital Association (ACA) Summit.
  • Showcase Companies and Keiretsu Forum's Involvement:
    Keiretsu Forum Mid-Atlantic, South-East, and Texas regions are sponsoring an impressive roster of enterprises, meticulously selected for their potential to transform their respective industries.
  • Keiretsu Forum has cultivated a legacy of investment that fosters innovation and industry advancement.
  • For additional information on the exemplary opportunities presented by Keiretsu Forum and attendance specifics for the ACA Summit's Innovation Funders Showcase, please contact Cindi Sutera at [email protected] or call at 610-613-2773.

SOHM, Inc. and Coastar Therapeutics Sign MoU and Announce Collaboration to Revolutionize Genome Editing Using Red Blood Cell Membrane Derived Carriers

Retrieved on: 
Lunedì, Aprile 1, 2024
Gene editing, Cell, IBN, Partnership, Tissue, Genetics, Medicine, Regenerative medicine, OTC, Cas9, Immune system, Therapy, Vaccine

Genome editing, particularly through the use of CRISPR-Cas9 technology, has emerged as a groundbreaking approach in the field of genetic research and therapeutics.

Key Points: 
  • Genome editing, particularly through the use of CRISPR-Cas9 technology, has emerged as a groundbreaking approach in the field of genetic research and therapeutics.
  • Coastar's red blood cell membrane derived carriers have shown immense potential in efficiently delivering therapeutic cargo into cells.
  • These carriers, derived from the natural membrane of red blood cells, possess several advantages, including biocompatibility, stability, and the ability to evade the immune system.
  • The integration of Coastar's red blood cell membrane derived carriers with SOHM's ABBIE protein-based system holds great promise for both in vitro and in vivo applications.

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

Retrieved on: 
Mercoledì, Marzo 27, 2024
Research, Dicarboxylic acid, AAV, Enzyme, Development, Gene editing, CAST, Cardiovascular disease, Haemophilia, Vivisection, Patient, Primate, RNA, DNA, Wave 1, Sale, Metagenomics, G&A, IPO, Ultra, Doctor of Philosophy, Protein, MBA, Genome, SMART, Factor VIII, CRISPR, Amyloidosis, MGX, AGT, Liver, LNP, Ionis, PAM, Vaccine

EMERYVILLE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today reported financial results for the full year ended December 31, 2023, and additional business updates.

Key Points: 
  • The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, cash used to fund our operations was $91.4 million for the year ended December 31, 2023.
  • R&D Expenses: Research and development (R&D) expenses were $94.4 million for the full year ended December 31, 2023.
  • G&A Expenses: General and administrative (G&A) expenses were $28.8 million for the full year ended December 31, 2023.

Factor Bioscience Expands Translational Science Team, Appoints Kyle Garland, Ph.D., as Director of Translational Science

Retrieved on: 
Martedì, Aprile 9, 2024
Cell engineering, Vanderbilt University, Development, Gene editing, Biotechnology, Entrepreneurship, Science, Research, Messenger, Therapy, DRS, Biological engineering, Chemical engineering, Lehigh University, Research fellow, Vaccine

CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science.

Key Points: 
  • CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science.
  • "We are excited to welcome three talented scientific professionals to Factor," said Dr. Matt Angel, Co-Founder, Chairman, and CEO of Factor.
  • "Dr. Garland, who is joined by Associate Scientists, Raven Hinkel and Elizabeth Belcher, has deep translational research expertise in mRNA and cell engineering.
  • The addition of Kyle and his team will enhance Factor's ability to support our strategic partners and accelerate our efforts to translate our technologies to new products."

Cibus Reports Fourth Quarter Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Marzo 21, 2024
Research, Farmer, Gene editing, Entrepreneurship, HT1, Seed, HT2, Net, Bayer, PSR, Breeding, CBUS, WOSR, European Parliament, Agriculture

We've made significant progress on the commercial front with several advancements of these developed traits, including transfers to customers.

Key Points: 
  • We've made significant progress on the commercial front with several advancements of these developed traits, including transfers to customers.
  • This vote was a significant milestone for our entire industry and is a crucial step that will help Cibus usher in the gene editing era."
  • 2 Cibus Powered™ is the internal Cibus trait standard that ensures each Cibus trait meets minimum efficacy and quality assurance commercial requirements.
  • Cibus will host a live webcast, Thursday, March 21, 2024, at 4:30 p.m. Eastern Standard Time to discuss its fourth quarter 2023 financial results and provide a business update.

Cibus Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2024

Retrieved on: 
Martedì, Marzo 19, 2024
Editorial, Culture, Organization, Regeneration, Entrepreneurship, MIC, Agriculture, SAN, HT1, AI, Hope, Seed, HT2, ITunes, PSR, Most, CBUS, Heart, Breeding, Food, Gene editing

Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions.

Key Points: 
  • Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions.
  • “We are extremely proud to be recognized by Fast Company as one of the world’s most innovative companies of 2024,” stated Rory Riggs, Co-Founder, Chairman, and CEO of Cibus.
  • The World's Most Innovative Companies stands as Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year.
  • This event celebrates the Most Innovative Companies honorees and provides an inside look at cutting-edge business trends and what it takes to innovate in 2024.